Skip to Main Content

Advertisement

Skip Nav Destination

Asciminib versus bosutinib in CML; dopamine signaling and hematopoietic stem cells; complement factor C5 and VTE risk

In this week’s episode, we’ll learn more about the efficacy of asciminib in patients with chronic myeloid leukemia who are resistant or intolerant to two or more tyrosine kinase inhibitors, discuss the role of dopamine signaling in hematopoietic stem and progenitor cell function, and learn more about elevated plasma concentration of complement factor C5 as a risk factor for venous thromboembolism.

Released November 25, 2021

The articles highlighted in this episode are listed below:

 
Close Modal

or Create an Account

Close Modal
Close Modal

Advertisement

X